Cargando…
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling
SIMPLE SUMMARY: Drug resistance is a long-standing impediment to effective systemic cancer therapy and acquired drug resistance is a growing problem for new therapeutics that otherwise have shown significant successes in disease control. Hepatocyte growth factor (HGF)/Met receptor pathway signaling...
Autores principales: | Cecchi, Fabiola, Rex, Karen, Schmidt, Joanna, Vocke, Cathy D., Lee, Young H., Burkett, Sandra, Baker, Daniel, Damore, Michael A., Coxon, Angela, Burgess, Teresa L., Bottaro, Donald P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857108/ https://www.ncbi.nlm.nih.gov/pubmed/36672409 http://dx.doi.org/10.3390/cancers15020460 |
Ejemplares similares
-
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
por: Zhu, M, et al.
Publicado: (2015) -
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
por: Affronti, Mary Lou, et al.
Publicado: (2018) -
Intracrine androgen biosynthesis and drug resistance
por: Penning, Trevor M., et al.
Publicado: (2020) -
Exploring the Intracrine Functions of VEGF-A
por: Wiszniak, Sophie, et al.
Publicado: (2021) -
Intracrine androgen biosynthesis, metabolism and action revisited
por: Schiffer, Lina, et al.
Publicado: (2018)